Currently out of the existing stock ratings of Chris Schott, 9 are a SELL (4.52%), 52 are a HOLD (26.13%), 138 are a BUY (69.35%).

Chris Schott

Work Performance Price Targets & Ratings Chart

Analyst Chris Schott, currently employed at JPMORGAN, carries an average stock price target met ratio of 43.71% that have a potential upside of 20.19% achieved within 238 days.

Chris Schott’s has documented 396 price targets and ratings displayed on 30 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on REGN, Regeneron Pharmaceuticals at 31-Mar-2025.

Wall Street Analyst Chris Schott

Analyst best performing recommendations are on EQRX (EQRX).
The best stock recommendation documented was for EQRX (EQRX) at 8/16/2022. The price target of $5.5 was fulfilled within 3 days with a profit of $0.67 (13.87%) receiving and performance score of 46.24.

Average potential price target upside

of $119.69 (13.56%) on REGN (REGENERON PHARMACEUTICALS).
of $93.68 (22.78%) on IDXX (IDEXX LABORATORIES).
of $66.99 (50.78%) on AGN (ALLERGAN PLC).

ABBV AbbVie BHC Bausch Health Companies BMY Bristol-Myers Squibb Company HZNP Horizon Pharma PLC IDXX IDEXX Laboratories JNJ Johnson & Johnson LLY Eli Lilly and Company MRK Merck mpany PFE Pfizer TEVA Teva Pharma Industries Ltd ADR ELAN Elanco Animal Health HSKA Heska MYL Viatris AGN Allergan plc CHRS Coherus BioSciences MNK Mallinckrodt plc RPRX Royalty Pharma Plc VTRS Viatris EQRX EQRx ZTS Zoetis ENDP Endo International PLC PRGO Perrigo Company PLC REGN Regeneron Pharmaceuticals TXMD TherapeuticsMD KALA Kala Pharmaceuticals OGN Organon PCRX Pacira Pharmaceuticals BIIB Biogen AMRX Amneal Pharmaceuticals, Common Stock GILD Gilead Sciences

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Terence Flynn (MORGAN STANLEY)